{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasms+of+Thyroid+and+Other+Endocrine+Glands", "query": { "condition": "Malignant Neoplasms of Thyroid and Other Endocrine Glands" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasms+of+Thyroid+and+Other+Endocrine+Glands&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T20:40:06.630Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04985604", "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Solid Tumor", "CRAF Gene Amplification", "RAF1 Gene Amplification", "BRAF Gene Fusion", "BRAF Fusion", "CRAF Gene Fusion", "CRAF Fusion", "RAF1 Gene Fusion", "RAF1 Fusion", "Thyroid Cancer, Papillary", "Spitzoid Melanoma", "Pilocytic Astrocytoma", "Pilocytic Astrocytoma, Adult", "Non Small Cell Lung Cancer", "Non-Small Cell Adenocarcinoma", "Colorectal Cancer", "Pancreatic Acinar Carcinoma", "Spitzoid Malignant Melanoma", "Bladder Cancer", "Bladder Urothelial Carcinoma", "MAP Kinase Family Gene Mutation", "RAF Mutation" ], "interventions": [ { "name": "Tovorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Day One Biopharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 23, "start_date": "2021-07-15", "completion_date": "2024-07-08", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-05-21T20:40:06.630Z", "location_count": 8, "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04985604" }, { "nct_id": "NCT01502410", "title": "Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Hepatocellular Carcinoma", "Papillary Thyroid Cancer", "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Childhood Liver Cancer", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Thyroid Cancer", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 20, "start_date": "2012-01", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2018-06-26", "last_synced_at": "2026-05-21T20:40:06.630Z", "location_count": 83, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 70 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01502410" }, { "nct_id": "NCT05786924", "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Histiocytic Neoplasm", "Histiocytosis", "BRAF Gene Mutation", "BRAF V600E", "BRAF V600 Mutation", "BRAF Mutation-Related Tumors", "BRAF", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Cancer", "Recurrent Lung Cancer", "Recurrent Lung Non-Small Cell Carcinoma", "NSCLC", "Solid Tumor", "Solid Carcinoma", "KRAS G12D", "KRAS G12V", "KRAS Mutation-Related Tumors", "NRAS Gene Mutation", "Thyroid Cancer", "Thyroid Carcinoma", "Colorectal Cancer", "Colorectal Carcinoma", "Recurrent Histiocytic and Dendritic Cell Neoplasm", "Brain Metastases", "Recurrent NSCLC", "KRAS G13C", "Acquired Resistance to KRAS G12C Inhibitor", "KRAS G12A", "KRAS G12F", "KRAS G12R", "KRAS G13D" ], "interventions": [ { "name": "S241656", "type": "DRUG" }, { "name": "FOLFOX6/FOLFOX7", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 554, "start_date": "2023-04-18", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-05-21T20:40:06.630Z", "location_count": 10, "location_summary": "Gilbert, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05786924" }, { "nct_id": "NCT05907304", "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "Naporafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Erasca, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "12 Years to 99 Years" }, "enrollment_count": 86, "start_date": "2023-08-17", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-05-21T20:40:06.630Z", "location_count": 14, "location_summary": "San Francisco, California • New Haven, Connecticut • Sarasota, Florida + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05907304" }, { "nct_id": "NCT03157128", "title": "A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Medullary Thyroid Cancer", "Colon Cancer", "Any Solid Tumor" ], "interventions": [ { "name": "LOXO-292", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 857, "start_date": "2017-05-02", "completion_date": "2027-02", "has_results": true, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-05-21T20:40:06.630Z", "location_count": 41, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03157128" }, { "nct_id": "NCT03093909", "title": "Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Neoplasm of Bone and Articular Cartilage", "Malignant Neoplasms of Female Genital Organs", "Malignant Neoplasms of Independent (Primary) Multiple Sites", "Malignant Neoplasms of Lip Oral Cavity and Pharynx", "Malignant Neoplasm of Male Genital Organs", "Malignant Neoplasms of Mesothelial and Soft Tissue", "Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma", "Malignant Neoplasms of Thyroid and Other Endocrine Glands", "Malignant Neoplasms of Urinary Tract", "Melanoma and Other Malignant Neoplasms of Skin" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": 44, "start_date": "2017-11-22", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-05-21T20:40:06.630Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03093909" }, { "nct_id": "NCT03896958", "title": "The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer, All Types", "Cancer of Liver", "Cancer of Stomach", "Cancer of Head and Neck", "Cancer of Rectum", "Cancer of Kidney", "Cancer of Esophagus", "Cancer of Colon", "Cancer Skin", "Cancer of Cervix", "Cancer, Metastatic", "Cancer of Larynx", "Cancer of Neck", "Cancer of Lung", "Cancer of Brain and Nervous System", "Cancer of Vulva, Disseminated", "Cancer of Pancreas", "Sarcoma", "GIST", "Small-cell Lung Cancer", "Adenocarcinoma Lung", "Cancer of Prostate", "Cancer, Advanced", "Adrenal Cancer", "Testicular Cancer", "Uterine Cancer", "Bronchoalveolar Cell Lung Cancer", "Cancer Unknown Primary", "Glioblastoma Multiforme", "Oligodendroglioma", "Breast Cancer", "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Cholangiocarcinoma", "Squamous Cell Carcinoma", "Transitional Cell Carcinoma", "Cancer, Other", "Cancer, Anal", "Melanoma", "Cancer, Bile Duct", "Cancer, Bladder", "Cancer Cords Vocal", "Cancers Cell Neuroendocrine", "Cancer Differentiated Poorly", "Cancer, Anaplastic Thyroid" ], "interventions": [], "intervention_types": [], "sponsor": "SpeciCare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Month to 99 Years" }, "enrollment_count": 1000, "start_date": "2019-03-21", "completion_date": "2024-03-12", "has_results": false, "last_update_posted_date": "2020-12-04", "last_synced_at": "2026-05-21T20:40:06.630Z", "location_count": 1, "location_summary": "Gainesville, Georgia", "locations": [ { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896958" }, { "nct_id": "NCT06583395", "title": "Quest to Analyze One Thousand Humans Meditating", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Amyotrophic Lateral Sclerosis (ALS)", "Angina, Stable", "Anxiety", "Asthma", "Atrial Fibrillation", "Cancer Brain", "Cancer, Breast", "Cancer Colon", "Cancer, Lung", "Cancer, Ovarian", "Cancer Prostate", "Cancer Skin", "Throat Cancer", "Lymphoma", "Cancer, Thyroid", "Cancer, Other", "Cerebral Palsy", "Chronic Fatigue Syndrome", "Cluster Headache", "Chronic Obstructive Pulmonary Disease (COPD)", "Chronic Kidney Diseases", "Crohn Disease", "Deafness", "Depression", "Diabetes", "Eczema", "Epilepsy", "Fibroids", "Fibromyalgia", "Heart Failure", "Hypertension", "Hyperthyroidism", "Hypothyroidism", "Irritable Bowel Syndrome (IBS)", "Infertility", "Lyme Disease", "Macular Degeneration", "Migraine", "Multiple Allergies", "Multiple Sclerosis", "Osteoarthritis", "Osteoporosis", "Ovarian Cysts", "Parkinson Disease", "Phantom Limb Pain", "Psoriasis", "Post Traumatic Stress Disorder (PTSD)", "Rheumatoid Arthritis", "Sjogrens Disease", "Spinal Cord Injury", "Spinal Stenosis", "Stroke", "Tension Headache", "Tinnitus", "Ulcerative Colitis" ], "interventions": [ { "name": "Advanced multi-component meditation practice", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Tobias Moeller-Bertram", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 3000, "start_date": "2021-12-05", "completion_date": "2025-03-25", "has_results": false, "last_update_posted_date": "2024-11-01", "last_synced_at": "2026-05-21T20:40:06.630Z", "location_count": 1, "location_summary": "Palm Desert, California", "locations": [ { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06583395" }, { "nct_id": "NCT03435952", "title": "Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Neoplasm of Breast", "Malignant Neoplasms of Digestive Organs", "Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System", "Malignant Neoplasms of Female Genital Organs", "Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites", "Malignant Neoplasms of Independent (Primary) Multiple Sites", "Malignant Neoplasms of Lip Oral Cavity and Pharynx", "Malignant Neoplasms of Male Genital Organs", "Malignant Neoplasms of Mesothelial and Soft Tissue", "Malignant Neoplasms of Respiratory and Intrathoracic Organs", "Malignant Neoplasms of Thyroid and Other Endocrine Glands", "Malignant Neoplasms of Urinary Tract" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Clostridium Novyi-NT", "type": "BIOLOGICAL" }, { "name": "Doxycycline", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-07-10", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-05-21T20:40:06.630Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03435952" }, { "nct_id": "NCT05538130", "title": "A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Glioma", "Thyroid Cancer", "Non-Small Cell Lung Cancer", "Malignant Neoplasms", "Brain Neoplasms", "Advanced or Metastatic Solid Tumors", "HGG", "LGG", "Low Grade Glioma", "High Grade Glioma", "Differentiated Thyroid Cancer", "NSCLC (Non-small Cell Lung Cancer)" ], "interventions": [ { "name": "PF-07799544", "type": "DRUG" }, { "name": "PF-07799933", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 124, "start_date": "2022-11-30", "completion_date": "2029-02-07", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-05-21T20:40:06.630Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05538130" } ] }